A groundbreaking clinical trial has revealed that a daily pill, daraxonrasib, can significantly extend the survival time for patients suffering from pancreatic cancer, often considered the world's deadliest cancer. Experts are hailing this development as a “gamechanger” and one of the most significant breakthroughs in decades, offering renewed hope for a disease with historically few effective treatments.

Pancreatic cancer is notoriously difficult to treat, often diagnosed at advanced stages when it has already spread to other parts of the body. For years, scientists have strived to find innovative solutions for this aggressive form of cancer, as more than half of patients receive a diagnosis only after the disease has metastasized. The introduction of daraxonrasib, a smart drug, is now seen as a potential catalyst for a treatment revolution.

The pivotal trial involved 500 patients, all of whom had advanced pancreatic cancer that had spread. The results, presented at the American Society of Clinical Oncology’s (Asco) annual meeting in Chicago, demonstrated that the pill effectively doubled survival time compared to traditional chemotherapy, and with fewer side-effects. Patients treated with daraxonrasib lived for an average of 13.2 months, a substantial improvement over the 6.6 to 6.7 months observed in patients undergoing chemotherapy.

Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center and an Asco expert in gastrointestinal cancers, described the findings as “landscape-changing” and indicative of “unprecedented survival.” She shared a deeply personal reaction to the results, expressing profound emotion after 16 years of treating pancreatic cancer patients. Dr. Julie Gralow, Asco’s chief medical officer and executive vice-president, further emphasized the trial's impact, calling it a “grand slam.”

Daraxonrasib operates by targeting the Kras protein, which is a primary driver for nearly all pancreatic cancers. The drug's mechanism involves gluing molecules together to effectively grab and deactivate Kras. This protein is part of the Ras family of genes, which, when mutated, can cause cancer cells to continuously receive signals to grow and divide unchecked, leading to cancer proliferation and spread. More than 90% of patients with pancreatic ductal adenocarcinoma (mPDAC), the most common form of pancreatic cancer, possess a mutation in the Kras gene, specifically a Ras G12 variant, resulting in an overactive Kras protein.

As a new class of Ras inhibitor, specifically a Ras(On) multi-selective inhibitor, daraxonrasib possesses the unique ability to turn off the Kras protein, thereby halting cancer growth, regardless of the presence or specific type of Kras variant. Dr. Shroff noted that targeting Kras has long been considered the “holy grail” in treating most malignancies, particularly pancreatic cancer due to its ubiquitous presence and its role as an early driver of cancer growth. She concluded that “the Ras revolution is here, and this study is proof of principle that targeting Kras in pancreatic cancer is feasible and effective.”

Advocacy groups have also expressed immense optimism. Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, highlighted the discovery as one of the most significant advancements in treatment she has witnessed. Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, found the results “exciting,” emphasizing that daraxonrasib has provided patients with “months more precious time with their loved ones.” Both organizations underscore the critical next step: ensuring that these life-extending drugs are made widely available to patients, especially given that tragically, half of all people with pancreatic cancer die within just three months of diagnosis.

Beyond pancreatic cancer, experts in Chicago also indicated that since Ras genes fuel other cancers, this breakthrough in targeting Kras holds promise for similar advancements in the treatment of lung and colon cancers, where analogous drugs are currently under investigation.